Triastek

Triastek is a Chinese pharmaceutical technology company founded in 2015 that develops 3D-printed drugs using its proprietary MED (Melt Extrusion Deposition) process . The company was established by CEO Senping Cheng, who described its early challenge as building from a "三无" (three-nothings) state: no printers, no established pharmaceutical materials for printing, and no validated in-vivo drug release methods . Its technology enables programmable control of drug release timing, location, and rate through precise internal microstructures—what it terms "structural pharmaceutics" .

The company has positioned itself as a global leader in the field, claiming four firsts in drug 3D printing as of 2023: highest patent volume (over 20% of global filings), most products in regulatory pipelines (3 of 4 globally with IND approvals in both China and the US), largest production line capacity, and being the only Chinese pharmaceutical firm selected for the US FDA's Emerging Technology Program . In September 2025, it obtained China's first manufacturing license for 3D-printed drugs, for a Nanjing facility with annual capacity of 300 million tablets .

Triastek has partnered with major global pharmaceutical companies including Eli Lilly, Boehringer Ingelheim, Merck, and Siemens, as well as domestic firms like Sperogenix . Its investors include Dalton Venture, which led its 2020 funding round, and Yunqi Capital . The company raised 150 million yuan in a Pre-C round in September 2023 .